期刊文献+

RP-HPLC法测定大鼠血浆中萘哌地尔羟基代谢物浓度及药代动力学 被引量:1

RP-HPLC determination of concentration of metabolite of naftopidil in rat plasma and pharmacokinetics
下载PDF
导出
摘要 目的:建立 RP-HPLC 法测定萘哌地尔羟基代谢物 RS-1-[4-(2-羟苯基)-1-哌嗪基]-3-(1-萘氧基)-2-丙醇(BWJ)在大鼠血浆的药物浓度及药代动力学,为此化合物的进一步开发提供依据。方法:以 Kromasil C_(18)柱(150mm×4.6mm 5μm)分离,萘哌地尔(NAF)为内标,流动相为甲醇-乙腈-磷酸盐缓冲液,检测波长为235nm。结果:BWJ 保留时间为10.3min,血药浓度在0.012~3.6mg·L^(-1)范围内线性关系良好,绝对回收率为72.0%~86.8%。大鼠十二指肠给予20mg·kg^(-1)后,药代动力学过程符合二室开放模型,t_(1/2α)、t_(1/2β)分别为(0.426±0.116)h,(2.69±0.222)h。结论:BWJ 吸收迅速,分布广泛,胆汁、尿、粪便中排泄量少,蛋白结合率高。 Objective: To establish a method for determining the concentration of RS - 1 - [ 4 - ( 2 - hydroxypbenyl) - 1 - piperazinyl ] - 3 - ( 1 - naphthoxy) - 2 - propanol ( BWJ ) metabolite of naftopidil in rat plasm and to study the pharmacokinetic profile of BWJ in rats and to provide pharmacokinetic data for BWJ' s further exploitation. Methods: A stainless steel column packed with C18 (Kromasil, 150 mm × 4. 6 mm 5 μm) was used, naftopidil (NAF) was chosen as the internal standard. The mobile phase was a mixture of methanol, acetonitrile and phosphate buffer and the detective wavelength is at 235 nm. Results:The retention time of BWJ was 10. 3 min. A good linear relationship of plasma concentration between 0. 012 -3.6 mg·L^-1 was observed. The mean absolute recovery was 72. 0% -86. 8%. The concentration - time curve of BWJ in rats conforms to two - compartment open model after administrated 20 mg ·kg^-1 to rats by duodenum. The t1/2α and t1/2β were(0. 426 ±0. 116)h, (2. 69 ±0. 222)h respectively. Condusion:BWJ is quickly absorbed from intestinal tract and distributed into tissues widely. It is excreted little in the bile, urine and feces but has a high protein -binding rate.
出处 《药物分析杂志》 CAS CSCD 北大核心 2006年第5期609-613,共5页 Chinese Journal of Pharmaceutical Analysis
基金 国家自然科学基金(30060087) 贵州省科技基金重点项目(计[2002(3014)])资助课题
关键词 RS-1-[4-(2-羟苯基)-1-哌嗪基]-3-(1-萘氧基)-2-丙醇(BWJ) 萘哌地尔(NAF) 药代动力学 反相高 效液相色谱法 KS - 1 - [ 4 - ( 2 - hydroxyphenyl ) - 1 - piperazinyl ] - 3 = ( 1 - naphthoxy) - 2 - propanol (BWJ) naftopidil (NAF) pharmacokinetics RP - HPLC
  • 相关文献

参考文献11

二级参考文献15

  • 1於东晖,万里涛,楼雅卿.高效液相色谱法测定生物样品中萘哌地尔浓度[J].药学学报,1995,30(4):286-290. 被引量:9
  • 2[1]Hieble JP, Caine M, Zalaznik E. In vitro characterization of the alpha-adrenoceptors in human prostate [J]. Eur J Pharmacol,1985,107(2):111~117.
  • 3[2]Hieble JP, Bylund DB, Clarke DE, et al. International Union of Pharmacology X.recommendation for nomenclature of α1-adren oceptors consensus update[J]. Pharmacol Rev,1995,47(2):267~269.
  • 4[3]Nasu K, Moriyama N, Fukasawa R, et al. Quantification and distribution of α1-adrenoceptor subtype mRNAs in human proximal urethra[J]. Br J Pharmacol,1998,123(7):1289~1293.
  • 5[4]Mariyama N, Kurimoto A, Horic S, et al. Detection of α1-adrenoceptor subtypes in human hypertrophied prostate by in situ hybridization[J]. Histochem J,1996,28(2):283~288.
  • 6[5]Takei R,Ikegaki I, Shibata K, et al. Naftopidil, a novel α1-adrenoceptor antagonist, diaplays selective inhibition of canine prostatic pressure and high affinity binding to cloned human α1-adrenoceptors[J]. Jpn J Pharmacol,1999,79(4):447~454.
  • 7[6]Niebch G, Locher M, Borbe HO. Metabolic fate of the novel antihypertensive drug Naftopidil[J]. Arzneimitteforschung,1991,41(10):1027~1032.
  • 8[7]Takagi N, Ishii M, Takeda K, et al. Pharmacokinetics of Naftopidil (KT-611) in hypertensive patients with renal impairment or normal renal function[J]. J Clin Ther Med,1992,8(Suppl 3):S109~S122.
  • 9[8]Farthing MJ, Alstead EM, Abrams SM, et al. Pharmacokinetics of Naftopidil, a novel anti-hypertensive drug,in patients with hepatic dysfunction[J]. Postgrad Med J,1994,70(823):363~366.
  • 10[9]Yasuda K, Yamanishi T, Tojo M, et al. Effect of Naftopidil on urethral obstruction in benign prostatic hyperplasia: assessment by urodynamic studies [J]. Prostate,1994,25(1):46~52.

共引文献36

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部